Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erel Joffe

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Cancer Cell|May 22, 2022
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignanciesRobert Stuver, Gunjan L Shah, Neha S Korde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Cancer Cell|May 22, 2022
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignanciesRobert Stuver, Gunjan L Shah, Neha S Korde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 7